Merck & Co. (NYSE: MRK) announced that its respiratory syncytial virus (RSV) vaccine, CAPVAXIVE, has been added to the publicly funded adult immunization program in Ontario, Canada.
The filing indicates that this inclusion means the vaccine will be available to eligible adults in the province at no cost. CAPVAXIVE is Merck's RSV vaccine candidate.
The news was reported by Benzinga on September 28, 2026.
